IRIDEX (IRIX) CFO Romeo Dizon Buys $1.1K of Stock

IRIDEX Corporation's Chief Financial Officer, Romeo Dizon, recently increased his personal stake in the company. On June 12, 2026, Dizon purchased 975 shares of IRIDEX, trading under the ticker IRIX on NasdaqCM, for $1.14 each. This purchase was valued at approximately $1,111.50.

Insider Buying and Selling at IRIDEX Corporation

Romeo Dizon, the CFO of IRIDEX, has been actively buying shares throughout June 2026. On June 12, he acquired 975 shares at $1.14 each. Earlier in the month, he made several other purchases: 1,675 shares on June 11 at the same price, 2,400 shares on June 8 at $1.12, 2,521 shares on June 5 at $1.15, and 2,400 shares on June 3 at $1.17. These transactions were not part of a pre-planned trading program. Additionally, on May 26, 2026, IRIDEX's President and CEO, Patrick Mercer, sold 19,233 shares at $1.01 each.

Other Institutional Activity in IRIDEX

Several institutional investors have also shown activity in IRIDEX. Vanguard Capital Management LLC added 514,593 shares, bringing its total to 514,593 shares valued at approximately $519,739. Renaissance Technologies LLC increased its holdings by 25,067 shares to a total of 396,627 shares, valued around $400,593. Geode Capital Management, LLC boosted its position by 24,951 shares, ending with 160,159 shares worth about $161,796. Meanwhile, Citadel Advisors LLC significantly increased its stake by 26,456 shares, resulting in 60,851 shares valued at approximately $61,460.

IRIDEX Corporation Stock Up 70.1%

Shares of IRIDEX, listed on NasdaqCM under the ticker IRIX, recently traded around $1.14. The company has a market capitalization of about $20.54 million. With a forward P/E ratio of 59.0 and a beta of 0.657, IRIDEX's stock has seen a 52-week low of $0.87 and a high of $1.65. The stock's 50-day moving average stands at $1.06, while the 200-day moving average is $1.17. IRIDEX maintains a current ratio of 1.916 and a quick ratio of 1.014, with a debt-to-equity ratio of 90.363.

Analysts Set New Price Targets

Analysts have set optimistic targets for IRIDEX. Roth MKM has maintained a buy rating with a price target of $6.25, while Roth Capital also holds a buy rating with a slightly higher target of $6.5. Stifel Nicolaus has maintained a hold rating, setting a price target at $2.0 as of March 27, 2024. Overall, the consensus target price for IRIDEX is $2.75, based on one analyst opinion.

About IRIDEX Corporation

IRIDEX Corporation, based in Mountain View, California, is a healthcare company specializing in medical devices. It provides laser systems, delivery devices, and consumable instruments for treating eye diseases. The company's products are used in the treatment of glaucoma, retinal disorders, and other sight-threatening conditions. Founded in 1989, IRIDEX serves ophthalmologists and medical facilities worldwide through its sales force and international distributors.

Bottom Line

IRIDEX Corporation's CFO, Romeo Dizon, has been actively increasing his shareholding in the company, indicating his confidence in its future. The company's stock, trading on NasdaqCM, has seen varied institutional activity, with several funds increasing their stakes. Analysts remain optimistic about IRIDEX's prospects, maintaining buy ratings from major firms. These insider and institutional moves, along with analyst targets, are crucial indicators for investors tracking the company.